Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
170M
-
Number of holders
-
229
-
Total 13F shares, excl. options
-
157M
-
Shares change
-
-286K
-
Total reported value, excl. options
-
$3.76B
-
Value change
-
+$21.9M
-
Put/Call ratio
-
0.8
-
Number of buys
-
108
-
Number of sells
-
-103
-
Price
-
$23.95
Significant Holders of ACADIA PHARMACEUTICALS INC - Common Stock, $0.0001 par value (ACAD) as of Q2 2023
276 filings reported holding ACAD - ACADIA PHARMACEUTICALS INC - Common Stock, $0.0001 par value as of Q2 2023.
ACADIA PHARMACEUTICALS INC - Common Stock, $0.0001 par value (ACAD) has 229 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 157M shares
of 170M outstanding shares and own 92.27% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (42.9M shares), VANGUARD GROUP INC (13.9M shares), BlackRock Inc. (10M shares), RTW INVESTMENTS, LP (9.78M shares), PRICE T ROWE ASSOCIATES INC /MD/ (6.01M shares), EcoR1 Capital, LLC (5.99M shares), STATE STREET CORP (5.42M shares), FMR LLC (5.32M shares), D. E. Shaw & Co., Inc. (5.26M shares), and MORGAN STANLEY (3.73M shares).
This table shows the top 229 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.